Core Insights - Magnus Tolleshaug, the Chief Executive Officer of Vistin Pharma ASA, purchased 30,000 shares at an average price of NOK 21.10 per share on February 20, 2026 [1] - Following this transaction, Magnus Tolleshaug now holds a total of 105,000 shares in Vistin Pharma ASA [1] Company Summary - Vistin Pharma ASA is experiencing insider trading activity, indicating potential confidence from its leadership in the company's future performance [1] - The average purchase price of NOK 21.10 per share may reflect the current valuation and market sentiment towards Vistin Pharma ASA [1]

Core Viewpoint - The Board of Directors will propose a cash dividend of up to NOK 1.50 per share for the accounting year of 2025, with payments scheduled for May and November 2026 [1] Dividend Details - The proposed dividend will be paid partly with NOK 1 in May 2026 and up to NOK 0.50 in November 2026 [1] - The formal decision regarding the dividend will be made at the Annual General Meeting on 20 May 2026 [1] Key Dates - Last day including right: 21 May 2026 [1] - Ex-date: 22 May 2026 [1] - Record date: 26 May 2026 [1] - Payment date (on or about): 29 May 2026 [1] - Date of approval: 20 May 2026 [1] Future Communication - Key information regarding the second dividend payment planned for November will be communicated in due time [1]

Core Insights - Vistin Pharma ASA reported strong financial results for Q4 2025, marking a record year with all-time high revenue and EBITDA [1] Financial Performance - Q4 2025 revenue reached MNOK 111, a slight decrease from MNOK 114 in Q4 2024, despite a record high sales volume increase of 9%, impacted by lower global metformin prices [2] - Full year 2025 revenue was an all-time high of MNOK 452, up from MNOK 430 in 2024, with a sales volume increase of 12% [2] - Q4 2025 EBITDA was MNOK 26, down from MNOK 28 in Q4 2024, influenced by a favorable sales volume but affected by product mix [3] - Full year 2025 EBITDA reached an all-time high of MNOK 115, a 10% increase from MNOK 104 in 2024 [3] - Earnings per share for 2025 increased to NOK 1.69 from NOK 1.42 in 2024, reflecting a 19% growth [3] Management Commentary - The CEO expressed satisfaction with the 2025 results, highlighting the company's ability to grow both top and bottom lines through effective commercial execution [4] Financial Position - The company maintains a strong balance sheet with an equity ratio of 75% and a net cash position of MNOK 16 as of year-end [4] Dividend Proposal - Based on preliminary results, the Board of Directors plans to propose an ordinary cash dividend of up to NOK 1.50 per share, to be distributed in two parts: NOK 1 in May and up to NOK 0.50 in November [5]

Company Overview - Vistin Pharma ASA is a Norwegian pharmaceutical company specializing in the production of Metformin Hydrochloride (API) and Direct Compressible lubricated granules [2] - The company is a dedicated European Metformin producer, positioning itself as a key supplier to leading pharmaceutical companies [2] - Vistin Pharma is headquartered in Oslo, Norway, and operates a dedicated manufacturing facility in Kragerø with a team of highly qualified employees [2] Upcoming Financial Results - Vistin Pharma will release its fourth quarter and preliminary 2025 results on February 12, 2025 [1] - A conference call for shareholders and interested parties will take place on the same day at 08:30 CET, including a Q&A session following the management discussion [1] - The conference call will be conducted in English and will be accessible via web and audio [1]

Core Insights - Vistin Pharma ASA reported a revenue increase in Q3 2025, reaching MNOK 109, up from MNOK 106 in Q3 2024, driven by a 10% higher sales volume [1] - Year-to-date revenue for 2025 is MNOK 342, an 8% increase from MNOK 316 in the same period last year [1] - The company's EBITDA for Q3 2025 was MNOK 28, slightly down from MNOK 29 in Q3 2024, impacted by lower global metformin prices [1] - Year-to-date EBITDA for 2025 stands at MNOK 89, a 16% increase from MNOK 77 in YTD 2024 [1] - Net profit for Q3 2025 was MNOK 18.5, compared to MNOK 16.6 in the previous year [2] - The company achieved an all-time high production volume of 1,600 MT of metformin in the quarter [2] Financial Performance - Q3 2025 revenue: MNOK 109, up 2.8% from Q3 2024 [1] - YTD 2025 revenue: MNOK 342, an 8% increase from YTD 2024 [1] - Q3 2025 EBITDA: MNOK 28, down from MNOK 29 in Q3 2024 [1] - YTD 2025 EBITDA: MNOK 89, up 16% from YTD 2024 [1] - Q3 2025 net profit: MNOK 18.5, compared to MNOK 16.6 in Q3 2024 [2] Production and Operations - All-time high production volume of metformin: 1,600 MT in Q3 2025 [2]

Company Overview - Vistin Pharma ASA (VISTN) is a Norwegian pharmaceutical company specializing in the production of Metformin Hydrochloride (API) and Direct Compressible lubricated granules [2] - The company is a dedicated European Metformin producer, positioning itself as a key supplier to leading pharmaceutical companies [2] Upcoming Financial Results - Vistin Pharma will release its third quarter and year-to-date 2025 results on October 31, 2025 [1] - A conference call for shareholders and interested parties will take place on the same day at 08:30 CET, including a Q&A session following the management discussion [1] Communication Channels - The conference call will be available via web and audio, with specific access points provided for participants [1][2] - For further inquiries, contact information for the CFO, Alexander Karlsen, is available [2]

Financial Performance - Vistin Pharma ASA reported second quarter revenue of MNOK 118, an increase from MNOK 106 in Q2 2024, driven by a 17% higher sales volume [1] - For the first half of 2025, revenue reached MNOK 233, up from MNOK 210 year-to-date in 2024, reflecting an 11% increase [1] - EBITDA for Q2 2025 was MNOK 30, compared to MNOK 27 in Q2 2024, marking an 11% increase [2] - Year-to-date EBITDA for the first half of 2025 was MNOK 60, up from MNOK 48 in the same period last year, representing a 27% increase [2] - The net profit for the first half of 2025 was MNOK 40.2, compared to MNOK 26.8 in the previous year [2] Shareholder Returns - A cash dividend of NOK 1.25 per share was distributed to shareholders in June 2025 [2]

Company Overview - Vistin Pharma ASA is a Norwegian pharmaceutical company specializing in the production of Metformin Hydrochloride (API) and Direct Compressible lubricated granules [3] - The company is a dedicated European Metformin producer, positioning itself as a key supplier to leading pharmaceutical companies [3] Upcoming Financial Results - Vistin Pharma will release its second quarter and year-to-date 2025 results on August 15, 2025 [1] - A conference call for shareholders and interested parties will take place on the same day at 08:30 CET, including a Q&A session following the management discussion [1] Communication Channels - The conference call will be accessible via web and audio through specified access points [1] - Webcast and telephone conference registration links are provided for participants [2]

Core Points - Vistin Pharma ASA held its annual general meeting on May 22, 2025, in Oslo, Norway [1] Group 1 - The minutes from the annual general meeting are attached for review [3]

Group 1 - Øystein Stray Spetalen has requested not to be re-elected as a board member of Vistin Pharma ASA [1] - The Election Committee assessed the implications of this request and concluded that Spetalen will not be replaced, resulting in a reduction of one board member [2] - The recommendation submitted on 13 March 2025 remains unchanged, except for the withdrawal of Item 9 from the annual general meeting agenda [2][3]